Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Hemlibra

- PMLiVE

Genentech increases investment to $2bn for US manufacturing site

Roche and Genentech have a current commitment of $50bn for US manufacturing

- PMLiVE

Genentech reports positive trial results for obesity treatment

The treatment is designed to tackle obesity by reducing appetite and regulating blood sugar

- PMLiVE

Genentech announces positive clinical results for BTK inhibitor MS treatment

Multiple sclerosis affects more than 2.9 million people globally

- PMLiVE

Genentech starts construction on manufacturing facility in North Carolina, US

The $700m project is part of Roche’s $50bn investment in the US

- PMLiVE

Roche’s Genentech enters $765m autoimmune disease partnership with Repertoire

The collaboration will leverage Repertoire’s immune mapping DECODE platform

- PMLiVE

Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke

TNKase is the first stroke medicine to be approved by the regulator in almost three decades

- PMLiVE

Sobi receives NICE recommendation for Altuvoct in severe haemophilia A

Approximately 7,700 people in England are living with the genetic bleeding disorder

- PMLiVE

Sobi receives MHRA approval for Altuvoct in severe or moderate haemophilia A

The factor VIII replacement therapy has been authorised to treat and prevent bleeding in children and adults

- PMLiVE

Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study

The inherited bleeding disorder accounts for up to 85% of the 1,125,000 global haemophilia cases

- PMLiVE

Roche’s Genentech acquires Regor Pharmaceuticals’ CDK inhibitors for $850m upfront

One of the candidates included in the deal has already shown promise in a phase 1a advanced breast cancer study

- PMLiVE

Roche’s Genentech and Sangamo enter neurodegenerative disease partnership worth over $1.9bn

According to WHO, neurological conditions are now the leading cause of ill health and disability worldwide

- PMLiVE

Pfizer shares positive late-stage results for haemophilia A gene therapy

The rare bleeding disorder occurs in approximately 25 in every 100,000 male births globally

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links